In preclinical models of HER2-positive and trastuzumab-resistant breast cancer, HSP90 inhibitors, including NVP-AUY922 and a carbamate derivative, have demonstrated significant efficacy by inhibiting HSP90AA1 [70]. The gene discussed is ERBB2; the disease is breast carcinoma.